Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Diabetes Mellitus Type 2, Social Determi...
Phase NA
Enrollment 412
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this project is to test a novel bedside SDOH screening intervention coupled with post-discharge navigation for hospitalized patients with a diabetes diagnosis to reduce unmet social needs, compared to usual care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: REDDCAT2 Post-Discharge Navigation — Those in the REDDCAT2 intervention group will be partnered with a patient navigator whose role will be to review the results of the screening survey completed at the beginning of the study. The patient navigator will help coordinate the participant's care before leaving the hospital and for 90 days after. Together, the participant and navigator will form an action plan intended to help address personal, social, or community factors affecting the participant's health. The navigator is expected to contact the participant every 2 weeks, though this can be adjusted based on their preference.
  • Other: Treatment as Usual (TAU) — TAU participants will receive standard care from the UMass Memorial Healthcare (UMMH) hospitalist team as appropriate. Participants will receive a printed list of community resources. No study-related patient navigation support will be provided. In 2024, Centers for Medicare and Medicaid Services mandated social determinants of health (SDOH) screening for inpatients. UMMH will use a checklist social needs screener. It will be up to the hospitalist teams to act on SDOH screening results. The UMMH hospitalist teams may consult endocrinology and/or inpatient social services to provide support and consultation for all patients regardless of study participation or group assignment. If medically appropriate, the endocrinology service may manage medications and provide referrals for continued treatment post discharge. All services that are normally provided by hospital care teams will remain available.

Primary Outcomes

  • Time to hospital service use post-discharge (90 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-08
Completion: 2029-05-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 412 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Massachusetts, Worcester
Collaborators: National Institute of Nursing Research (NINR), University of Michigan
Contact Information
Study Contact:
Suzanne Mitchell, MD, MS
774-441-6225
Suzanne.Mitchell2@umassmed.edu
Barbara De La Cruz
774-443-2246
Barbara.DeLaCruz@umassmed.edu
Suzanne Mitchell
774-442-3748
REDDCAT2@umassmed.edu
UMASS Memorial Healthcare System
Interventions
  • Behavioral: REDDCAT2 Post-Discharge Navigation — Those in the REDDCAT2 intervention group will be partnered with a patient navigator whose role will be to review the results of the screening survey completed at the beginning of the study. The patient navigator will help coordinate the participant's care before leaving the hospital and for 90 days after. Together, the participant and navigator will form an action plan intended to help address personal, social, or community factors affecting the participant's health. The navigator is expected to contact the participant every 2 weeks, though this can be adjusted based on their preference.
  • Other: Treatment as Usual (TAU) — TAU participants will receive standard care from the UMass Memorial Healthcare (UMMH) hospitalist team as appropriate. Participants will receive a printed list of community resources. No study-related patient navigation support will be provided. In 2024, Centers for Medicare and Medicaid Services mandated social determinants of health (SDOH) screening for inpatients. UMMH will use a checklist social needs screener. It will be up to the hospitalist teams to act on SDOH screening results. The UMMH hospitalist teams may consult endocrinology and/or inpatient social services to provide support and consultation for all patients regardless of study participation or group assignment. If medically appropriate, the endocrinology service may manage medications and provide referrals for continued treatment post discharge. All services that are normally provided by hospital care teams will remain available.
Study Locations (1 sites)
UMASS Memorial Healthcare System, Worcester, Massachusetts 01665 United States
Eligibility Criteria
Inclusion Criteria: * adult aged 18 years or older * diagnosed with type 2 diabetes * hospitalized at Univ of Massachusetts-affiliated hospital * endorsed at least 1 unmet social need via screening survey Exclusion Criteria: * pregnancy * discharge to short or long-term nursing facility or hospital * medical contraindication * cognitive impairment * unable to provide informed consent
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This prospective clinical study aims to evaluate the safety and efficacy of autologous adipose-derived stromal vascular fraction (SVF), enriched with mesenchymal stem cells (ADSCs), for the treatment of Type 2 Diabetes Mellitus (T2DM). Adipose tissue will be harvested using a 1210-nm diode laser-assisted selective photochemical stimulation technique (One-STEP™ method), followed by centrifugation without enzymatic digestion. The isolated SVF will be injected endoluminally into the duodenal submucosa during the same surgical procedure. Five adult patients with T2DM will be followed for six months to assess metabolic control, pancreatic function, and quality of life outcomes.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Autologous Adipose-Derived Stromal Vascular Fraction (SVF) — Autologous adipose tissue will be harvested using a 1210-nm diode laser-assisted liposuction technique (One-STEP™). The lipoaspirate will undergo double centrifugation without collagenase digestion to isolate stromal vascular fraction enriched with mesenchymal stem cells. The isolated SVF will be immediately injected into the duodenal submucosa during the same operative session.

Primary Outcomes

  • Change in Fasting Plasma Glucose (mg/dL) (Baseline and 6 months post-procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-20
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kaiser Clinic and Hospital
Contact Information
Study Contact:
Luiz Gustavo' Quadros, PhD
+55 17 98138-8737
gustavo_quadros@hotmail.com
Interventions
  • Biological: Autologous Adipose-Derived Stromal Vascular Fraction (SVF) — Autologous adipose tissue will be harvested using a 1210-nm diode laser-assisted liposuction technique (One-STEP™). The lipoaspirate will undergo double centrifugation without collagenase digestion to isolate stromal vascular fraction enriched with mesenchymal stem cells. The isolated SVF will be immediately injected into the duodenal submucosa during the same operative session.
Study Locations (1 sites)
Kaiser Clinica, São Jose Do Rio Preto, São Paulo 15.015-110 Brazil
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Both sexes * Diagnosis of Type 2 Diabetes Mellitus for less than 10 years * BMI ≥ 25 kg/m² * HbA1c between 7.5% and 9.5% * C-peptide \> 1.0 nmol/L * Use of metformin and/or pioglitazone, with or without sulfonylurea Exclusion Criteria: * Type 1 Diabetes Mellitus or autoimmune diabetes * Positive anti-GAD antibodies * Pregnancy or breastfeeding * Use of insulin therapy * Use of SGLT2 inhibitors * Use of DPP-4 inhibitors * Use of GLP-1 receptor agonists * Unknown duration of diabetes
Conditions Type 2 Diabetes
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this randomised controlled trial is to investigate the effectiveness of periodic CGM (continuous glucose monitoring) to support a person-centered approach versus self-monitoring of blood glucose (SMBG) in adults with type 2 diabetes on glucose control and patient reported outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Periodic CGM group with data analysis report- Intervention group — The patients are also instructed to continue to perform SMBG by finger prick if they experience symptoms of hypo- or hyperglycemia. During visit 0 (baseline) the patients is also instructed about how they can log in to the National Diabetes Register (NDR) to access their own NDR's recorded data and use the diabetes questionnaire.

Primary Outcomes

  • HbA1c (change at week 16)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-01
Completion: 2026-12
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sophiahemmet University
Collaborators: Swedish Diabetes Foundation, OneTwo Analytics AB, Sophiahemmet
Principal Investigators:
  • Unn-Britt Johansson (PRINCIPAL_INVESTIGATOR) - Sophiahemmet University
Contact Information
Study Contact:
Unn-Britt Johanssson, Professor
+4684062902
unn-britt.johansson@shh.se
Unn-Britt Johansson, PhD
Sophiahemmet University
Interventions
  • Behavioral: Periodic CGM group with data analysis report- Intervention group — The patients are also instructed to continue to perform SMBG by finger prick if they experience symptoms of hypo- or hyperglycemia. During visit 0 (baseline) the patients is also instructed about how they can log in to the National Diabetes Register (NDR) to access their own NDR's recorded data and use the diabetes questionnaire.
Study Locations (1 sites)
Sophiahemmet University, Stockholm, Sweden
Eligibility Criteria
Inclusion Criteria: * Adults aged 18-80 years * Type 2 diabetes with a duration of \> 6 months * HbA1c 45-70 mmol/mol * Have a smartphone * Experience of self-monitoring of blood glucose prior to the study start Exclusion Criteria: * Prandial insulin * Pregnancy or planning pregnancy during the study * Breastfeeding * Renal disease with estimated glomerular filtration rate (eGFR) \<45 mL/ min/1.73 m2 * Active malignancy or under investigation for malignancy * Severe visual impairment * Severe skin allergy that inhibits the use of a continuous glucose monitoring device * Glucocorticoids (systemic) * Planned or currently using weight reduction medications, programs, or surgery * Cognitively or psychologically unable to participate and read instructions * Enrolled in other clinical trials * Eating disorders
Conditions Type 2 Diabetes Mellitus (T2DM), Atheros...
Phase PHASE2
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study will test whether a low-cost anti-inflammatory medicine called colchicine can help protect the blood vessels of people with type 2 diabetes. Diabetes speeds up hardening of the arteries (atherosclerosis), partly because of ongoing low-grade inflammation. Colchicine has already been shown to help prevent heart attacks and strokes in people who already have heart disease; this study looks at whether it can also help prevent early blood vessel damage before heart disease develops. Around 300 adults with type 2 diabetes will be randomly assigned to take colchicine or a placebo (dummy pill) once daily for 24 weeks, in addition to their usual diabetes and heart-risk medications. Neither participants nor the study team will know who is taking colchicine or placebo. The main measurement will be the change in the thickness of the wall of the neck (carotid) artery, measured by ultrasound, which is an early sign of blood vessel disease. The study will also look at markers of inflammation in the blood, blood vessel stiffness and function, and changes in the gut bacteria.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Colchicine 0.5 MG Oral Tablet Once Daily — For 24 weeks
  • Drug: Placebo — Matched placebo tablets (identical in size, shape, taste, and packaging to colchicine), once daily, for 24 weeks

Primary Outcomes

  • Change from Baseline in Mean-Maximum Carotid Intima-Media Thickness (Mean-Maximum CIMT) (Baseline and 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-24
Completion: 2027-07-31
Eligibility
Age: 21 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tan Tock Seng Hospital
Collaborators: Nanyang Technological University
Principal Investigators:
  • Rinkoo Dalan, MD, PhD (PRINCIPAL_INVESTIGATOR) - Tan Tock Seng Hospital
Contact Information
Study Contact:
Sanchalika Acharyya, PhD, MPH
96150202
sanchalika.acharyya@nhghealth.com.sg
Shirley Lin Shangmei
ttsh.p2p.research@nhghealth.com.sg
Rinkoo Dalan, MD, PhD
65-6357100
rinkoo.dalan@nhghealth.com.sg
Tan Tock Seng Hospital
Interventions
  • Drug: Colchicine 0.5 MG Oral Tablet Once Daily — For 24 weeks
  • Drug: Placebo — Matched placebo tablets (identical in size, shape, taste, and packaging to colchicine), once daily, for 24 weeks
Study Locations (1 sites)
Tan Tock Seng Hospital, Singapore, Singapore 308433 Singapore
Eligibility Criteria
Inclusion Criteria: * T2DM on stable diabetes medications (no change in last 3 months) * At least one other comorbidity of hypertension, dyslipidaemia and/or obesity (BMI ≥27), with no previous history of ASCVD * Able to provide informed consent Exclusion Criteria: 1. Recent hospitalization or acute infections within last 2 weeks. 2. Current Treatment with corticosteroids or immunosuppressive agents 3. Pre-existing malignancies or other terminal conditions with limited prognosis 4. Pregnancy 5. Breastfeeding 6. Inability to provide written consent 7. Renal impairment (eGFR\< 60ml/min) 8. Liver cirrhosis or ALT/AST \>3x ULN 9. Pharmacogenomics indicative of adverse effects 10. Hypersensitivity to the active substance or to the following excipients: Lactose, Maize starch, Sodium laurilsulfate, Magnesium stearate 11. Known blood dyscrasia 12. Women of childbearing age who are keen to conceive in the next 1 year 13. Taking a strong P-glycoprotein inhibitor (e.g. cyclosporine, ranolazine) or a strong CYP3A4 inhibitor 14. Known myositis with raised creatine kinase with statins (statin myopathy). 15. Gout attack within the last 1 year 16. Currently taking Aspirin 17. Taking any oral contraceptives
Conditions Healthy Volunteer, Type 2 Diabetes
Phase PHASE1
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study is testing a new medicine that might help treat people with type 2 diabetes. The study is conducted to see if the new medicine can lower high sugar levels in the blood. The purpose of the study is to see if the new study medicine is safe and how well is tolerated by the body. There will be two groups of partici-pants in this study: healthy participants and participants with type 2 diabetes. Participant will either get study medicine (NNC9733-0001) or placebo (a treatment that has no active medicine in it). Which treatment the participant gets is decided by chance. Which dose (strength) the participant get is determined by when participant enter the study. Participant will get one dose which will be injected into the area around abdomen (belly) by the medical staff. The number of injections (up to 4 injections) will depend on the group the participant is assigned to. Larger doses require multiple injections. The study will last for about 40 weeks (10 months).

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: NNC9733-0001 — Administered a single dose of NNC9733-0001.
  • Drug: Placebo — Administered a single dose of matching NNC9733-0001 placebo.

Primary Outcomes

  • Number of treatment emergent adverse events (TEAEs) (From dosing (day 1) until end of study (EOS) visit (week 36))
  • Number of hypoglycaemic episodes (From dosing (day 1) until end of study (EOS) visit (week 36))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-11-25
Completion: 2028-03-15
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novo Nordisk A/S
Principal Investigators:
  • Clinical Transparency dept. 2834 (STUDY_DIRECTOR) - Novo Nordisk A/S
Contact Information
Study Contact:
Novo Nordisk
(+1) 866-867-7178
clinicaltrials@novonordisk.com
Interventions
  • Drug: NNC9733-0001 — Administered a single dose of NNC9733-0001.
  • Drug: Placebo — Administered a single dose of matching NNC9733-0001 placebo.
Study Locations (1 sites)
Profil Institut für Stoffwechselforschung GmbH, Neuss, 41460 Germany
Eligibility Criteria
Inclusion Criteria: All participants * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study. * Male, or female of nonchildbearing potential Healthy participants * Age 18-45 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) between 18.5 and 29.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening. * Glycosylated haemoglobin (HbA1c) less than or equal to (≤) 6.4 percent (%) (47 millimoles per mole (mmol/mol)) at screening. * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, Electrocardiography (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator. Participants with T2DM * Age 18-64 years (both inclusive) at the time of signing the informed consent. * BMI between 20.0 and 34.9 kg/m\^2 (both inclusive) at screening. * HbA1c 6.5-9.0% (47.5-74.9 mmol/mol) at screening. * Diagnosed with type 2 diabetes mellitus (T2DM) greater than or equal to (≥) 180 days before screening. * Stable daily dose(s) of metformin or in combination with SGLT2 inhibitors and/or dipeptidyl peptidase IV (DPP-4) inhibitors are allowed, within 90 days before screening. Exclusion Criteria: * Screening alanine transaminase (ALT) values greater than (\>) upper limit of normal (ULN) +10 per-cent (%), AST values \>ULN +20%, or total bilirubin \>ULN. * Renal impairment, defined as estimated glomerular filtration rate (eGFR) less than (\<) 60.0 millilitre per minute per 1.73-meter square (mL/min/1.73m\^2), at screening. * Clinical evidence of Chronic Kidney Disease (CKD) and/or urinary albumin:creatinine ratio (UACR) \>30 milligram per gram (mg/g). * Presence or history of cardiovascular disease, including stable and unstable angina pectoris, myocardial infarction, transient ischaemic attack, stroke, cardiac decompensation, clinically significant arrhythmias, or clinically significant conduction disorders. Healthy participants * Any disorder, which in the investigator's opinion, might jeopardise participants' safety or compliance with the protocol. * Supine blood pressure at screening outside the range of 90-139 millimetres of mercury (mmHg) for systolic or 50-89 mmHg for diastolic. Participants with T2DM - Any disorder, except for mild conditions under stable treatment associated with T2DM, which in the investigator's opinion might jeopardise participant safety or compliance with the protocol. • Supine blood pressure at screening outside the range of 90-159 mmHg for systolic or 50-99 mmHg for diastolic. This exclusion criterion also pertains to those participants who are receiving antihypertensive treatment.

Collection of Human Metabolic Tissues

NCT02861781
Recruiting
Conditions Obesity, Insulin Resistance, Diabetes Me...
Phase Not Applicable
Enrollment 270
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This project aims at identifying new determinants of type 2 diabetes in severe obesity. To do so, a biological collection, including tissues of interest in the field of metabolism, will be collected during bariatric surgery in obese patients. Three different groups of metabolic status of patients, corresponding to different stages of evolution of the disease, will be constituted: type 2 diabetes, insulin resistance, insulin sensitivity. The main objective is to compare, between these 3 groups of patients, several biological processes that may be involved in the pathophysiology of type 2 diabetes and disorders associated with obesity, including: * Abnormalities of the transcriptome, proteome, metabolome in all target tissues (plasma, serum, muscle, subcutaneous and visceral adipose tissue, omental artery, liver) * Identification of metabolic signatures, protein and miRNA in plasma * Immunoinflammatory response in adipose tissue * Polymorphisms SNP from whole blood * Histological analysis of tissue sections This main objective will be studied on samples taken at the time of surgery Secondary objectives will be to study the changes in metabolites, proteins and miRNA in plasma level 3 and 12 months after the completion of surgery, according to the initial metabolic state.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Collection of blood samples and tissues — Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits

Primary Outcomes

  • comparison of metabolites (At baseline (day of surgery))
  • comparison of proteins levels (At baseline (day of surgery))
  • comparison of miRNA (At baseline (day of surgery))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2016-02-02
Completion: 2028-09
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 270 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Montpellier
Principal Investigators:
  • Florence GALTIER (PRINCIPAL_INVESTIGATOR) - University Hospital, Montpellier
Contact Information
Study Contact:
Florence Galtier, MD
f-galtier@chu-montpellier.fr
Florence Galtier, MD
f-galtier@chu-montpellier.fr
Hôpital Saint Eloi
Florence Galtier, MD
Hôpital Saint Eloi
Interventions
  • Other: Collection of blood samples and tissues — Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
Study Locations (1 sites)
Hôpital Saint Eloi, Montpellier, 34295 France
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent 2. Age 18 - 65 years inclusive at surgery 3. IMC \> 35 4. Subject qualified for bariatric surgery (sleeve gastrectomy or gastric bypass) 5. Specific criteria : * Type 2 diabetes group (D) (90 patients) : type 2 diabetes according to ADA criteria * Insulin resistance non diabetes group (IR) (80 patients) : HOMA-IR criteria ≥ 3 * Insulin Sensitivity non diabetes group (N) (100 patients) : N1.HOMA-IR criteria \< 3 Non inclusion Criteria: 1. Vulnerability according to article L1121-6 of the Public Health Code 2. Protected adult or unability to give consent according to article L1121-8 of the Public Health Code 3. Unability to understand the design and aims of the study or to communicate with the investigator 4. Non affiliation to a social security system 5. Prior bariatric surgery (except lap-band procedure) 6. Serologic profile indicating hepatitis B, hepatitis C or HIV infection 7. Inflammatory, infectious or autoimmune disease (current or in the previous 3 month) 8. Malignancies within 5 years prior to inclusion or not considered as treated curatively 9. Concomitant use of steroids or NSAI or use in the 8 days before surgery 10. alcohol abuse/addiction 11. Anticipated poor compliance to study procedures 12. Other type of diabetes than type 2 Exclusion Criteria : 1. Cancelled bariatric surgery 2. Tissue collection not possible during the bariatric surgery
Conditions Non-Diabetic
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

In France, only the fasting blood glucose (FBG) measurement is recommended for diabetes screening. Ethnic heterogeneity and genetic polymorphisms specific to the Afro-Caribbean and Indo-Caribbean population in Guadeloupe justify the interest to early screen type 2 diabetes mellitus (T2DM). Our main objective is to estimate the prevalence of T2DM defined by oral glucose tolerance (OGTT) in subjects with risk factors for T2DM and not diagnosed with the FBG.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: After inclusion, the subjects will have an OGTT performed in the department of Diabetology. If the glucose blood levels remain normal after the OGTT, the test will be repeated after 12 months. A contr — After inclusion, the subjects will have an OGTT performed in the department of Diabetology. If the glucose blood levels remain normal after the OGTT, the test will be repeated after 12 months. A control of the HbA1c levels will be also performed associated with a physical examination.

Primary Outcomes

  • HbA1c levels > 5.7%, (baseline, 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-02-02
Completion: 2028-08-02
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Universitaire de la Guadeloupe
Principal Investigators:
  • Fritz-Line VELAYOUDOM, Doctor (PRINCIPAL_INVESTIGATOR) - CHU de la Guadeloupe
Contact Information
Study Contact:
Valérie HAMONY-SOTER
+590 590 93 46 77
valerie.soter@chu-guadeloupe.fr
Eunice NUBRET
eunice.nubret@chu-guadeloupe.fr
Valérie HAMONY-SOTER
+590590934686
valerie.soter@chu-guadeloupe.fr
Centre Hospitalier Universitaire de la Guadeloupe
Interventions
  • Diagnostic Test: After inclusion, the subjects will have an OGTT performed in the department of Diabetology. If the glucose blood levels remain normal after the OGTT, the test will be repeated after 12 months. A contr — After inclusion, the subjects will have an OGTT performed in the department of Diabetology. If the glucose blood levels remain normal after the OGTT, the test will be repeated after 12 months. A control of the HbA1c levels will be also performed associated with a physical examination.
Study Locations (1 sites)
Centre Hospitalier Universitaire de la Guadeloupe, Pointe-à-Pitre, Guadeloupe 97159 Guadeloupe
Eligibility Criteria
o Inclusion criteria : Adult subject (over 18 years and under 65 years old) Subjects of African or Indian origin and self-declared Normal FBG levels (110mg/dL) HbA1c levels between 5.7 and 6.4% One or more of the following factors: BMI \> 25 kg/m2, family history of T2DM in the 1st and 2nd familial degree, hypertension, dyslipidemia. Affiliation to the national social health system or equivalent Informed and written consent signed by the patient and the investigator (at the latest on the day of inclusion and before the completion of any research related exam) o Exclusion criteria : Pregnant or lactating woman Women with a history of gestational diabetes Polycystic ovary syndrome Endocrine, hepatic or renal diseases affecting glycemic control Treatment that affect the metabolism of glucose or insulin Refusal to participate Subjects without adequate or impaired decisional abilities for consent to research and placed under guardianship, curatorship or safeguard of justice, person participating in another research including an exclusion period still in progress, severely impaired physical and / or psychological health, which, according to the investigator, may affect the compliance of the study participant
Conditions Type 1 Diabetes, Type 2 Diabetes
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. There is evidence that α-cell proglucagon processing is subject to paracrine regulation by the β-cell3. It is unclear if the effects of GLP1R agonism on islet GLP-1 differ in Type 1 diabetes (T1DM) compared to T2DM. This experiment will examine the effect of glycemic control ± a GLP1R agonist on islet GLP-1 in people with (T2DM) and without (T1DM) β-cells.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Drug: Liraglutide Pen Injector — Liraglutide 0.6mg
  • Other: Saline Injections — Saline in syringes to serve as placebo for single blind study

Primary Outcomes

  • Effect of exendin 9-39 on fasting glucagon secretion rate before and after liraglutide treatment (The change in fasting glucagon secretion rate (saline vs. exendin 9-39) in the baseline study will be compared with the change in fasting glucagon secretion rate (saline vs. exendin 9-39) after 30 days of treatment with liraglutide (post-liraglutide))
  • Effect of exendin 9-39 on glucagon secretion rate during hyperglycemia before and after liraglutide (The change in glucagon secretion rate during hyperglycemia (saline vs. exendin 9-39) in the baseline study will be compared with the change (saline vs. exendin 9-39) after 30 days of treatment with liraglutide (post-liraglutide))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-10-03
Completion: 2029-03-31
Eligibility
Age: 25 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Adrian Vella, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Adrian Vella, MD
507-255-6515
vella.adrian@mayo.edu
Amy O'Byrne
507-255-8547
OByrne.Amy14@mayo.edu
Mayo Clinic in Rochester
Adrian Vella
Mayo Clinic in Rochester
Interventions
  • Drug: Liraglutide Pen Injector — Liraglutide 0.6mg
  • Other: Saline Injections — Saline in syringes to serve as placebo for single blind study
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Type 1 or type 2 diabetes treated with insulin Exclusion Criteria: 1. Age \< 25 or \> 70 years. 2. HbA1c \> 10.0% 3. For female subjects: positive pregnancy test at the time of enrollment or study 4. History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy. 5. Prior use of GLP-1 receptor agonists in the previous year. 6. Active systemic illness or malignancy. 7. Symptomatic macrovascular or microvascular disease.
Conditions Asthma
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to assess the concordance of international asthma guidelines in the diagnosis of asthma and explore the presence of airways disease using additional non-guideline physiologic criteria, such as IOS (impulse osciollometry), not included in the guidelines, but available in the Portsmouth lung function service.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Lung function tests — Pulmonary function tests

Primary Outcomes

  • International asthma guidelines scores (during study analysis 4 weeks after recruitment)
  • non-guideline physiologic criteria numbers (during study analysis 4 weeks after recruitment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-27
Completion: 2027-05-27
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Portsmouth Hospitals NHS Trust
Principal Investigators:
  • Anoop Chauhan (PRINCIPAL_INVESTIGATOR) - Portsmouth University Hospital Trust
Contact Information
Study Contact:
celia Selvin-Premkumar
02392 286000
celia.selvin-premkumar@porthosp.nhs.uk
Laura Marshall
02392286000
research.office@porthosp.nhs.uk
Portsmouth Hospitals University NHS Trust
Interventions
  • Other: Lung function tests — Pulmonary function tests
Study Locations (1 sites)
Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom
Eligibility Criteria
Inclusion Criteria: * The patient will meet all the following criteria to be considered eligible for the study: * Aged 18 years or over. * All patients who have attended full asthma workups from November 2021 till date * Willing and able to consent to use their data in this study (opt-out form or e-consent). * Patients referred to the Portsmouth asthma service for diagnosis and further management of presumed asthma. Comorbidities are common in asthma, thus patients with co-existing conditions such as obesity, bronchiectasis or COPD will be included. Exclusion Criteria: * The participant may not enter the study if either of the following apply: * Unable to comprehend the study and provide informed consent, e.g., insufficient command of English in the absence of someone who can adequately interpret. * Patients with other primary respiratory conditions, such as ILD.
Conditions Post Deployment Related Asthma, Asthma
Phase PHASE2
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Service men and women returning from deployment are significantly more likely to develop asthma and severe respiratory symptoms from airway obstruction. Why this happens is not well known, but exposure to diesel, burn pits, biomass smoke, and sandstorms are thought to play a role. Ultimately, patients with deployment related asthma develop a complex airway disease that does not respond well to standard asthma medications. Therefore, it is imperative that safe and affordable treatments that could improve quality of life and symptoms are studied. It has been previously shown that adult patients with poorly controlled asthma have an abnormal regulation of an amino acid called L-arginine and airway nitric oxide (FeNO), a gaseous molecule normally produced in the airways of healthy people. In healthy people, nitric oxide is present in amounts that help keep the airways open. However, in some patients with asthma, nitric oxide and L-arginine are often low. The investigators' preliminary data in obese asthmatics show that L-citrulline, which is an amino acid that can be metabolized into L-arginine, improved lung function and asthma control, while increasing the levels of FeNO. This is potentially shifting the paradigm in how investigators think of asthma management, as rising FeNO is often thought of being a bad sign. Based on this, the study investigators hypothesize that an L-citrulline-based drug strategy will normalize nitric oxide metabolism, suppress oxidative inflammatory responses and improve airway function in obese patients with asthma. The study proposal presents a clinical trial approach to treat deployment related asthma patients using L-citrulline as an add-on therapy to improve asthma control. If this confirms the investigators' previous study results, the investigators will be in route for developing the only precision-based therapy available to treat this asthma phenotype. These study results will potentially show that L-citrulline is a safe, tolerable medication that can make a significant impact on the respiratory health of a large segment of our active and veteran population at a reasonable cost.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: L-citrulline — 7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
  • Drug: Placebo — 7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)

Primary Outcomes

  • Change in Asthma Control Questionnaire (Through study completion, up to 22 weeks)
  • Change in FeNO values (Through study completion, up to 22 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-03-08
Completion: 2028-10
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Denver
Collaborators: National Jewish Health, United States Department of Defense
Principal Investigators:
  • Fernando Holguin, MD, MPH (PRINCIPAL_INVESTIGATOR) - University of Colorado Denver- Anschutz Medical Campus
Contact Information
Study Contact:
University of Colorado Asthma and Research Education Team
1-844-365-0852
asthmaresearh@ucdenver.edu
NJH SEALS Team
303-398-1748
DeploymentLungRes@njhealth.org
National Jewish Health
Cecile Rose, MD, MPH
National Jewish Health
Interventions
  • Drug: L-citrulline — 7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
  • Drug: Placebo — 7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
Study Locations (1 sites)
National Jewish Health, Denver, Colorado 80206 United States
Eligibility Criteria
Inclusion Criteria: * Adequate completion of informed consent process with written documentation * Male and female patients, 18 - 70 years old, inclusive * Meets criteria for deployment related asthma or DRA (New onset of persistent respiratory symptoms of cough, dyspnea, wheezing and/or chest tightness during or after post-9/11/2001 military deployment to Southwest Asia, accompanied by a post-bronchodilator increase in FEV1 ≥ 12% and an increase in FEV1 ≥ 200 milliliters on pulmonary function testing and/or methacholine challenge showing airways hyperresponsiveness with a 20 percent drop in FEV1 (PC\[-20\] FEV1) ≤ 16 mg/mL. ) Historical results from previous studies or documented in clinical records within the last 24 months are acceptable alternatives * Able to perform reproducible spirometry according to ATS criteria * All racial/ethnic backgrounds may participate * Smoking tobacco history ≤15 pack years and no smoking in the last 3 months * Suboptimal asthma control at baseline (ACQ ≥ 0.5 or ACT\<19) Exclusion Criteria: * Respiratory tract infection within the 4 weeks prior to Visit 0 * Pulmonary-related ER visit within the 4 weeks prior to Visit 0 * Oral or systemic corticosteroid burst (for any indication) within the 4 weeks prior to Visit 0. One-time doses, such as intra-articular injections into a shoulder or knee joint, require a 2-week washout prior to Visit 0 * Significant concomitant medical illness at the discretion of the PI, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases * Chronic renal failure (creatinine \> 2.0) at Visit 0 (Associated with higher ADMA levels) * Positive urine (or serum) pregnancy test at Visit 0 or at any time during the study * Intolerance or allergy to L-arginine or L-citrulline * Concomitant use of PDE5 drugs or oral mononitrates * Unable or unlikely to complete study assessments in the opinion of the Investigator * Study intervention poses undue risk to patient in the opinion of the Investigator
Conditions Pulmonary Disease, Asthma, Chronic Obstr...
Phase PHASE1
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Pulmonary Diseases

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: AlloRx — cultured allogeneic adult umbilical cord derived mesenchymal stem cells

Primary Outcomes

  • Safety (adverse events) (Four year follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2021-12-01
Completion: 2025-12
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Foundation for Orthopaedics and Regenerative Medicine
Principal Investigators:
  • Chadwick Prodromos, MD (PRINCIPAL_INVESTIGATOR) - The Foundation for Orthopaedics and Regenerative Medicine
Contact Information
Study Contact:
Chadwick Prodromos, M.D.
8476996810
research@ismoc.net
Medical Surgical Associates Center
Interventions
  • Biological: AlloRx — cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study Locations (1 sites)
Medical Surgical Associates Center, St John's, Antigua and Barbuda
Eligibility Criteria
Inclusion Criteria: * Diagnosis of pulmonary disease * Understanding and willingness to sign a written informed consent document Exclusion Criteria: * Active infection * Active cancer * Chronic multisystem organ failure * Pregnancy * Clinically significant Abnormalities on pre-treatment laboratory evaluation * Medical condition that would (based on the opinion of the investigator) compromise patient's safety. * Continued drug abuse * Pre-menopausal women not using contraception * Previous organ transplant * Hypersensitivity to sulfur

AYLo - AutoimmunitY and Loss of y

NCT06696027
Recruiting
Conditions Giant Cell Arteritis (GCA), Polymyalgia ...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims to systematically investigate hematopoietic mutations, such as hematopoietic (mosaic) loss of the Y chromosome (mLOY), focusing on their underlying causes, pathophysiological significance, patterns of manifestation, and impact on disease progression in autoimmune, rheumatologic disorders. This research seeks to bridge existing knowledge gaps by exploring how such mutations influence immune homeostasis, cellular function, and susceptibility to inflammation-driven pathologies. Through the integration of advanced immunological profiling, the study aspires to uncover key mechanisms that drive the initiation, progression, and complications of autoimmune rheumatic diseases. These analyses will combine single nucleotide polymorphisms (SNP) arrays, multiplex assays, transcriptomics, and flow cytometry staining of peripheral blood mononuclear cells to delineate the interplay between hematopoietic mutations and immune dysregulation. A further objective is the development of a multimodal framework for disease-specific characterization, enabling precise mapping of mutation-driven phenotypes across diverse autoimmune conditions. This framework will incorporate clinical, molecular, and imaging data. Additionally, the AYLo study aims to explore the potential role of mLOY and other hematopoietic mutations as biomarkers for disease stratification, prognosis, and therapeutic response. The findings may open avenues for personalized treatment approaches, leveraging the molecular insights to inform targeted interventions and improve patient outcomes in autoimmune rheumatic disorders. By integrating translational and basic science approaches, this study has the potential to redefine current paradigms in autoimmune disease research and therapy.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Single nucleotide polymorphisms (SNP) — Utilizing single nucleotide polymorphisms (SNP) genotyping mosaic loss of y (mLOY) of individual patient will be assessed.
  • Diagnostic Test: 3'mRNA sequencing — 3'mRNA sequencing analyzes gene expression profiles related to the immune response in different study cohorts, aiding in understanding the genetic underpinnings of inflammation and its association with mLOY.
  • Diagnostic Test: Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array — Used to measure cytokine levels in the serum of investigated patients, aiding in profiling inflammatory markers that are indicative of disease activity, response to treatment and consequence of mLOY..
  • Diagnostic Test: Flow Cytometry — Employed to analyze immune cell phenotypes in investigated cohorts. This test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and its association with mLOY.
  • Diagnostic Test: Laboratory assessment — Serum Chemistry
  • Diagnostic Test: Assessment of Pulmonary Involvement — Results of routine clinical assessment of pulmonary involvement (such as lung ultrasound, computed tomography, chest x-ray, whole-body plethysmography) will be compared to mLOY, ELISA/ Legendplex/ flow cytometry/ transcriptome analysis results.

Primary Outcomes

  • Quantification of the fraction of hematopoietic cells exhibiting mLOY. (Cross sectional. Newly diagnosed patients: At baseline and 12 months after diagnosis).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-15
Completion: 2026-07
Eligibility
Age: 50 Years and older
Sex: MALE
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Bonn
Contact Information
Study Contact:
Simon Michael Petzinna, MD
0049 151 382 337 07
Simon_Michael.Petzinna@ukbonn.de
Valentin Sebastian Schäfer, MD
0049 228 287 17000
valentin.schaefer@ukbonn.de
Valentin Sebastian Schäfer, MD
0049 228 287 17000
valentin.schaefer@ukbonn.de
Department of Rheumatology
Interventions
  • Diagnostic Test: Single nucleotide polymorphisms (SNP) — Utilizing single nucleotide polymorphisms (SNP) genotyping mosaic loss of y (mLOY) of individual patient will be assessed.
  • Diagnostic Test: 3'mRNA sequencing — 3'mRNA sequencing analyzes gene expression profiles related to the immune response in different study cohorts, aiding in understanding the genetic underpinnings of inflammation and its association with mLOY.
  • Diagnostic Test: Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array — Used to measure cytokine levels in the serum of investigated patients, aiding in profiling inflammatory markers that are indicative of disease activity, response to treatment and consequence of mLOY..
  • Diagnostic Test: Flow Cytometry — Employed to analyze immune cell phenotypes in investigated cohorts. This test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and its association with mLOY.
  • Diagnostic Test: Laboratory assessment — Serum Chemistry
Study Locations (1 sites)
Department of Rheumatology, Bonn, North Rhine-Westphalia 53127 Germany
Eligibility Criteria
Inclusion Criteria: * Male * \> 50 years * Diagnosis of arthritis (RA, PsA), collagen diseases (SLE, systemic sclerosis, Sjögren's syndrome, mixed connective tissue diseases), vasculitis (eGPA, GPA, MPA, IgG4-related disease, GCA, PMR), sarcoidosis, COPD, ILD or asthma bronchiale confirmed by the treating physician. Exclusion Criteria: * Female * \< 50 years Inclusion Criteria (Healthy controls): * Male * \> 50 years Exclusion Criteria (Healthy controls): * Female * \< 50 years * autoimmune, rheumatological diease * pulmonary precondition